BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 85 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,188 | -62.0% | 39,600 | 0.0% | 0.00% | -60.0% |
| Q2 2023 | $263,736 | -61.8% | 39,600 | +7.0% | 0.01% | -61.5% |
| Q1 2023 | $690,420 | -18.4% | 37,000 | -6.1% | 0.01% | -18.8% |
| Q4 2022 | $846,312 | +149.6% | 39,400 | +37.5% | 0.02% | +128.6% |
| Q3 2022 | $339,000 | -18.3% | 28,650 | -8.9% | 0.01% | -12.5% |
| Q2 2022 | $415,000 | +6.1% | 31,450 | +68.2% | 0.01% | +33.3% |
| Q1 2022 | $391,000 | +10.5% | 18,700 | +7.5% | 0.01% | +20.0% |
| Q4 2021 | $354,000 | -35.9% | 17,400 | -4.4% | 0.01% | -37.5% |
| Q3 2021 | $552,000 | -3.5% | 18,200 | -7.6% | 0.01% | 0.0% |
| Q2 2021 | $572,000 | -8.9% | 19,700 | +35.4% | 0.01% | -20.0% |
| Q1 2021 | $628,000 | +166.1% | 14,550 | +185.3% | 0.01% | +150.0% |
| Q4 2020 | $236,000 | +15.7% | 5,100 | +8.5% | 0.00% | 0.0% |
| Q3 2020 | $204,000 | – | 4,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |